Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2022 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...
November 07, 2022 08:01 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
November 01, 2022 16:15 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
October 03, 2022 16:20 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
September 28, 2022 06:45 ET | Source: TCR2 Therapeutics

gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in...
September 27, 2022 16:15 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
September 26, 2022 16:15 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
September 01, 2022 17:15 ET | Source: TCR2 Therapeutics

TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
August 08, 2022 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial...
August 01, 2022 17:15 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...